ATE241359T1 - Topische und systemische anwendung von buspiron und seinen derivaten zur behandlung von pathologischen zuständen, die mit immunantworten verbunden sind - Google Patents

Topische und systemische anwendung von buspiron und seinen derivaten zur behandlung von pathologischen zuständen, die mit immunantworten verbunden sind

Info

Publication number: ATE241359T1
Authority: AT; Austria
Prior art keywords: topical; treatment; buspiron; derivatives; immune responses
Prior art date: 1993-03-26

Application number

AT94911001T

Other languages

English (en)

Inventor

Richard J Sharpe

Kenneth A Arndt

Stephen J Galli

Peter C Meltzer

Raj K Razdan

Howard P Sard

Original Assignee

Beth Israel Hospital

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-26

Filing date

1994-03-28

Publication date

2003-06-15

1993-03-26 Priority claimed from US08/037,225 external-priority patent/US5631017A/en

1993-03-26 Priority claimed from US08/037,271 external-priority patent/US5484788A/en

1994-03-28 Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital

2003-06-15 Application granted granted Critical

2003-06-15 Publication of ATE241359T1 publication Critical patent/ATE241359T1/de

Links

230000000699 topical effect Effects 0.000 title abstract 2
230000001575 pathological effect Effects 0.000 title 1
230000009885 systemic effect Effects 0.000 title 1
241000124008 Mammalia Species 0.000 abstract 2
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 abstract 2
206010062016 Immunosuppression Diseases 0.000 abstract 1
229960002495 buspirone Drugs 0.000 abstract 1
239000003085 diluting agent Substances 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000007910 systemic administration Methods 0.000 abstract 1
238000011200 topical administration Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Immunology (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)

AT94911001T 1993-03-26 1994-03-28 Topische und systemische anwendung von buspiron und seinen derivaten zur behandlung von pathologischen zuständen, die mit immunantworten verbunden sind ATE241359T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/037,225 US5631017A (en)	1993-03-26	1993-03-26	Topical application of buspirone for treatment of pathological conditions associated with immune responses
US08/037,271 US5484788A (en)	1993-03-26	1993-03-26	Buspirone as a systemic immunosuppressant
PCT/US1994/003353 WO1994022448A1 (en)	1993-03-26	1994-03-28	Topical and systemic application of buspirone or derivatives thereof for treatment of pathological conditions associated with immune responses

Publications (1)

Publication Number	Publication Date
ATE241359T1 true ATE241359T1 (de)	2003-06-15

Family

ID=26713927

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94911001T ATE241359T1 (de)	1993-03-26	1994-03-28	Topische und systemische anwendung von buspiron und seinen derivaten zur behandlung von pathologischen zuständen, die mit immunantworten verbunden sind

Country Status (10)

Country	Link
EP (1)	EP0690715B1 (de)
JP (1)	JPH09502699A (de)
AT (1)	ATE241359T1 (de)
AU (1)	AU692764B2 (de)
CA (1)	CA2159091C (de)
DE (1)	DE69432749T2 (de)
DK (1)	DK0690715T3 (de)
ES (1)	ES2201074T3 (de)
PT (1)	PT690715E (de)
WO (1)	WO1994022448A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5521183A (en) *	1994-08-30	1996-05-28	Allergan	Use of 5-HT ligands as anti-pruritic agents
US5637314A (en) *	1995-06-07	1997-06-10	Beth Israel Deaconess Medical Center, Inc.	Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
EP0942727A1 (de) *	1996-04-08	1999-09-22	Sano Corporation	Transdermale abgabevorrichtung für azapironverbindungen
DE69900207T2 (de) *	1998-07-14	2001-11-22	Alcon Laboratories, Inc.	Verwendung von 11-(3-dimethylaminopropyliden)-6,11-dihydrodibenz[b,e]oxepin-2-essigsäure und deren pharmazeutisch annehmbaren salzen zur herstellung eines medikaments zur behandlung nicht-allergisch-bedingten augenentzündungen und zur prevention der okularen neovaskularisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE759371A (fr) *	1969-11-24	1971-05-24	Bristol Myers Co	Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) *	1972-12-06	1976-08-24	Mead Johnson & Company	Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4963557A (en) *	1987-09-28	1990-10-16	Smithkline Beecham Corporation	Immunomodulatory azaspiranes
EP0489108B1 (de) *	1989-08-21	1996-03-13	Beth Israel Hospital Association	Verwendung von Spiperone-derivate zur Immunosuppression
DK0520032T3 (da) *	1990-03-16	1999-06-14	Beth Israel Hospital	Anvendelse af spiperon som immunundertrykkende og antiinflammatorisk middel
SE513429C2 (sv) *	1992-06-03	2000-09-11	Syntello Inc	Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer

1994
- 1994-03-28 WO PCT/US1994/003353 patent/WO1994022448A1/en not_active Ceased
- 1994-03-28 CA CA002159091A patent/CA2159091C/en not_active Expired - Fee Related
- 1994-03-28 DK DK94911001T patent/DK0690715T3/da active
- 1994-03-28 ES ES94911001T patent/ES2201074T3/es not_active Expired - Lifetime
- 1994-03-28 DE DE69432749T patent/DE69432749T2/de not_active Expired - Fee Related
- 1994-03-28 EP EP94911001A patent/EP0690715B1/de not_active Expired - Lifetime
- 1994-03-28 AU AU63692/94A patent/AU692764B2/en not_active Ceased
- 1994-03-28 JP JP6522262A patent/JPH09502699A/ja active Pending
- 1994-03-28 AT AT94911001T patent/ATE241359T1/de not_active IP Right Cessation
- 1994-03-28 PT PT94911001T patent/PT690715E/pt unknown

Also Published As

Publication number	Publication date
WO1994022448A1 (en)	1994-10-13
AU692764B2 (en)	1998-06-18
CA2159091A1 (en)	1994-10-13
EP0690715A4 (de)	1997-09-03
JPH09502699A (ja)	1997-03-18
DK0690715T3 (da)	2003-09-22
AU6369294A (en)	1994-10-24
CA2159091C (en)	2006-12-19
DE69432749T2 (de)	2004-04-08
EP0690715B1 (de)	2003-05-28
DE69432749D1 (de)	2003-07-03
EP0690715A1 (de)	1996-01-10
PT690715E (pt)	2003-10-31
ES2201074T3 (es)	2004-03-16

Similar Documents

Publication	Publication Date	Title
ATE288749T1 (de)	2005-02-15	Verwendung von kannabidiol als entzündunghemmende mittel
NO881051D0 (no)	1988-03-09	Metoder for behandling av solskadet, human hud med retinoider.
SE8702109L (sv)	1987-11-24	Tetrahydronaftalen- och indanderivat
ATE290531T1 (de)	2005-03-15	Pyran-2-onen und 5,6-dihydropyran-2-onen brauchbar für die behandlung von hyperplasie und andere krankheiten
ATE132762T1 (de)	1996-01-15	Vorrichtung zur behandlung von entzündlichen, sich im anfangsstadium befindlichen hautveränderungen
DE69510696D1 (de)	1999-08-12	2-(2-amino-3-methoxyphenyl)-4-oxo-4h-(1)-benzopyran für die behandlung von proliferativer erkrankungen
AU6256996A (en)	1996-12-30	Use of vitamin D4 derivatives for treating skin disorders
BG101105A (bg)	1998-04-30	Заместени бензамидини, тяхното получаване и използването им като лекарствени средства
GR3006180T3 (de)	1993-06-21
DE3888994D1 (de)	1994-05-19	Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
NO890046D0 (no)	1989-01-05	Disubstituerte pyridiner.
ATE241359T1 (de)	2003-06-15	Topische und systemische anwendung von buspiron und seinen derivaten zur behandlung von pathologischen zuständen, die mit immunantworten verbunden sind
NO830527L (no)	1983-09-05	Analogifremgangsmaate for fremstilling av 2,3-diaryl-5-halogenthiofener
IT1252603B (it)	1995-06-19	2,4-diamino-6 piperidino pirimidina-3 ossido topico sul glande nel trattamento delle impotenze erettili
DE3851815D1 (de)	1994-11-17	Feldeffekttransistor und dessen Herstellungsmethode.
NO950925D0 (no)	1995-03-10	Preparat og fremgangsmåte for behandling av hårtap
DK0391185T3 (da)	1994-04-11	1,8-Naphthyridiner
DE59206872D1 (de)	1996-09-12	Verwendung von torasemid zur behandlung von hirnödemen
DE69220939D1 (de)	1997-08-21	Gegengift immunsera
DE69129693D1 (de)	1998-08-06	Verwendung von nickel und bromide ionen für die behandlung von psoriasis
FI844645L (fi)	1985-06-11	1,7-difenyl-3-metylaza-7-cyan-8 -metyl-nonan foer anvaendning vid bekaempning av sjukdomar.
DE69732108D1 (de)	2005-02-03	Topische verabreichung von bestimmten azapriranen zur vorbeugung oder behandlung von hautzuständen, die mit hautzellhyperproliferation und/oder immunologisch vermittelten krankheiten verbunden sind
ATE137955T1 (de)	1996-06-15	Verwendung von 1,2-dipalmitoyl-l-alpha- phosphatidyl-n,n-dimethylethanilamine in dermatologischen und kosmetischen zusammensetzungen
KR910019627A (ko)	1991-12-19	화상 국부치료용 냉각제
ATE52186T1 (de)	1990-05-15	Aldose-reductase-hemmer, nuetzlich bei der behandlung von glaukom.

Legal Events

Date

Code

Title

Description

2003-12-15

UEP

Publication of translation of european patent specification

Ref document number: 0690715

Country of ref document: EP

2008-12-15

REN

Ceased due to non-payment of the annual fee